Decera Clinical Education at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Decera Clinical Education exhibits at Booth 2123 at ASH 2026 in New Orleans. Its presence centres on clinician education in blood cancers, as it runs symposia on CAR T in lymphoma, bispecific antibodies in follicular and diffuse large B-cell lymphoma, and CLL evidence. It also runs a myeloma guideline quiz with the National Comprehensive Cancer Network and a symposium on systemic mastocytosis.
| Organization | ASH 2026 Attendance |
|---|---|
Decera Clinical Education Reston, VA | |
Accredited medical education company (Clinical Education Alliance) running clinician education programs and satellite symposia, with data and market-research services. | Booth Exhibiting at Booth 2123 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation CAR-T for relapsed B-cell lymphomas, from patient selection and referral to managing immune and nerve toxicities, survivorship, and off-the-shelf products. Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. Symposium Fri Dec 11 11:00am–2:00pm Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease Diagnosing systemic mastocytosis, separating indolent from advanced disease, preventing anaphylaxis, and choosing between symptom control and Kit-targeted drugs. Symposium Fri Dec 11 3:00pm–6:00pm Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies. Symposium Fri Dec 11 3:00pm–6:00pm Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions How bispecific antibodies for follicular and diffuse large B-cell lymphoma differ in structure, dosing, and safety, and how to sequence them in community care. |
Instantly find 20 buyers from Decera Clinical Education
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction